https://www.selleckchem.com/
Type A insulin resistance (IR) syndrome is a severe IR form caused by insulin receptor (INSR) gene defects. Anti-diabetic drugs including high-dose insulin and insulin-sensitizing agents often fail to control associated hyperglycemia. Therapy with recombinant human insulin-like growth factor 1 can be more effective, but it is expensive. We report a case of type A IR syndrome with an in-frame INSR heterozygous deletion (ΔLeu999) that was treated with a combination of conventional therapy and ipragliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor.